RTRAF and breast cancer: In our current studies, we revealed C14orf166 was overexpressed in breast cancer cells and tissues, it might be a novel oncogene, we further analyzed C14orf166 expression in a cohort of 121 samples by IHC, and investigated the correlation between C14orf166 expression and clinicopathological characteristics.